Three different groups of B-CLL patients were established retrospectively according to the expression of wild-type (wt) or mutated/deleted (mut) TP53 and wt or mut IGHV: TP53wtIGHVmut (nine patients), TP53wtIGHVwt (eight patients), and TP53mutIGHVwt (five patients) as good, intermediate, and poor prognostic groups (Table 5). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.